Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial
- 16 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 15 (3) , 209-216
Abstract
This study evaluated the effect of physiological l-thyroxine (L-T4) treatment on bone metabolism in patients with subclinical hypothyroidism. Sixty-six women with subclinical hypothyroidism (TSH 11.7 ± 0.8 mIU/l) were randomly assigned to receive L-T4 or placebo for 48 weeks. Sixty-one of 66 patients completed the study. Individual L-T4 replacement (mean dosage 85.5 ± 4.3 μg/day) was performed targeting euthyroid thyroid-stimulating hormone (TSH) levels. The primary outcome measure was 24- and 48-week change in markers of bone formation (total and bone alkaline phosphatase [ALP, bone ALP], osteocalcin [OC]) and resorption (pyridinoline [PYD] and deoxypyridinoline [DPD], C-terminal cross-linking telopeptide type I [CTX]). Secondary outcomes were 48-week changes in bone mineral density (BMD) of the lumbar spine and hip, measured by dual-energy X-ray absorptiometry. Compared with placebo, l-thyroxine (n=31) resulted in significant activation of bone turnover. Overall, a significant treatment effect was observed for DPD (between-group difference 16.0%; 95%CI, 10.9 to 21.1), CTX (29.9%; 95%CI, 23.3 to 36.5), and bone ALP (13.2%; 95%CI, 6.6 to 19.7) after 24 weeks. At the end of the study, lumbar BMD in the both treatment groups differed by 1.3% (95%CI, −2.9 to 0.5) with lower levels in l-thyroxine treated women. Significant difference in BMD between groups was also observed at the trochanter. We conclude that physiological l-thyroxine treatment accelerates bone turnover reflecting early activation of bone remodeling units in the initial replacement of subclinical hypothyroidism. The observed bone loss could be interpreted as an adaptive mechanism on decreased bone turnover in preexistent hypothyroidism, and not as l-thyroxine-induced clinically important bone loss. However, long-term studies are needed to confirm this assumption.Keywords
This publication has 26 references indexed in Scilit:
- TSH-Controlledl-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study)The Journal of Clinical Endocrinology & Metabolism, 2001
- Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.1994
- Influence of Clinical Characteristics and Parameters Associated with Thyroid Hormone Therapy on the Bone Mineral Density of Women Treated with Thyroid HormoneThyroid®, 1994
- Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosisClinical Endocrinology, 1993
- Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: A randomized, prospective studyThe American Journal of Medicine, 1993
- Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSHJournal of Endocrinological Investigation, 1991
- Bone Mineral Density in Premenopausal Women Receiving Long-term Physiological Doses of LevothyroxineJAMA, 1991
- A DOUBLE‐BLIND CROSS‐OVER 12‐MONTH STUDY OF l‐THYROXINE TREATMENT OF WOMEN WITH ‘SUBCLINICAL’ HYPOTHYROIDISMClinical Endocrinology, 1988
- Normal and Pathological Remodeling of Human Trabecular Bone: Three Dimensional Reconstruction of the Remodeling Sequence in Normals and in Metabolic Bone Disease*Endocrine Reviews, 1986
- SPINAL BONE MINERAL CONTENT IN MYXOEDEMA AND THYROTOXICOSIS. EFFECTS OF THYROID HORMONE(S) AND ANTITHYROID TREATMENTClinical Endocrinology, 1983